– CANADA, Toronto – Titan Medical Inc. (TSX: TMD | Nasdaq: TMDI), a medical device company focused on the design and development of robotic surgical technologies for single access surgery, today announced the election of Paul Cataford, Anthony Giovinazzo and Cary Vance to its Board of Directors, effective on September 30th.
In addition, the Board elected Paul Cataford as Lead Independent Director for a one-year term.
The new directors join David McNally, Chairman of the Board, CEO and President of Titan Medical, and Director Stephen Randall, who recently retired from the company as CFO after serving the Company for over 10 years. The Board now consists of a majority of independent corporate directors.
“We strategically sought this strong team, with its significant experience leading young companies with innovative technologies through highly regulated environments to commercialization,” said Chairman and CEO, David McNally. “We’ve had a very productive first meeting, designating committee chairmanships for governance, reporting and communication, and compensation. This active board is already undertaking the initiative to develop and execute a comprehensive investor communications strategy based on the best practices of similar development stage companies.”
About Paul Cataford
Mr. Cataford is the CEO and co-founder of Zephyr Sleep Technologies Inc., a medical device company specializing in the treatment and diagnoses of sleep-disordered breathing. He brings significant technology transfer and early-stage company experience to Titan Medical’s board and has served as an independent corporate director on a number of public boards of directors at companies listed on the TSX, Nasdaq and TSXV including Sierra Wireless, Inc., Trakopolis IoT Corp., SemiBioSys Genetics Inc., and AGJunction Inc. Mr. Cataford has a Bachelor of Science degree in Mechanical Engineering from Queen’s University, an MBA specializing in Finance from Schulich School of Business at York University, and is a graduate of the Institute of Corporate Directors – Directors College, Rotman School of Business at the University of Toronto.
About Anthony Giovinazzo
Mr. Giovinazzo is a Director and Governance/Nominating Committee Chair on Titan Medical’s board of directors. As such, he will drive continuous improvement of the Company’s governance practices and has already overseen the appointment of qualified independent committee chairs and a lead independent director. Mr. Giovinazzo is a director and executive chairman on the board of Sublimity Therapeutics, a private late clinical-stage biopharmaceutical company addressing gastrointestinal and autoimmune diseases. He is a co-inventor of the recent FDA approved drug Kynmobi, developed by Cynapsus Therapeutics Inc. (Nasdaq: CYNA) where Mr. Giovinazzo was also CEO and a director until Cynapsus was acquired in an industry-leading all-cash transaction with Sunovion Pharmaceuticals Inc. for CAD $841 million. In 2017, Mr. Giovinazzo was chosen as the inaugural recipient of the Bloom Burton Award. Mr. Giovinazzo has a Chartered Director and Audit Committee Certification from The Directors College and the DeGroote School of Business at McMaster University. He received a Bachelor of Arts degree in Economics and Accounting from McMaster University and an MBA from IMD Geneva, Switzerland.
About Cary Vance
Mr. Vance is a Director and the Company’s Compensation Committee Chair and will lead and update the Company’s compensation policies and philosophies. Mr. Vance serves on the AdvaMed Accel Board of Directors and is currently Principal, Vance Consulting Group, LLC., and was most recently President and CEO at OptiScan Biomedical Corporation. He previously served as President and CEO at Myoscience Incorporated, and President and CEO of Hansen Medical Inc. Prior to Hansen, Mr. Vance served in various global executive leadership roles at Teleflex, Covidien and GE Healthcare. Mr. Vance is Lean/Six Sigma Black Belt certified and earned a Bachelor of Arts degree in Economics and an MBA from Marquette University.
About Titan Medical
Titan Medical Inc. is focused on robotic-assisted technologies for application in minimally invasive surgery. Enos, by Titan Medical, is being developed to become the new standard of care in robotic single access surgery and comprises a surgeon-controlled patient cart that includes a dual-view camera system with 3D and 2D high-definition vision systems and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provides an ergonomic interface to the MIS procedure performed through the patient cart. With the Enos system, Titan intends to initially pursue gynecologic surgical indications.
For more information: https://titanmedicalinc.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
